- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis
DARZALEX®▼ (daratumumab) Receives Positive CHMP Opinion for the Treatment of Multiple Myeloma in Patients who have Received At Least One Prior Therapy
Janssen’s first-in-class CD38-directed monoclonal antibody now recommended for approval earlier in the treatment pathway in combination with two standard of care regimens
Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies
First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens as Maintenance Therapy in Patients who have Already Achieved Viral Suppression
Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions
Agreements with DayTwo, the Weizmann Institute of Science and Caelus Health Focus on Promoting Health through Microbiome Innovation
IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy
First therapy specifically indicated for this rare blood cancer; represents fifth indication for IMBRUVICA in the U.S.
Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)
Phase 1b/Phase 2 studies planned in multiple myeloma and solid tumors